Home > Boards > US Listed > Biotechs >

Synaptogenix (SNPX)

SNPX RSS Feed
Add SNPX Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, Cyosol, Battle Ready
Search This Board: 
Last Post: 3/2/2021 1:21:35 AM - Followers: 92 - Board type: Free - Posts Today: 2


 

Description:
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. For more information, visit: https://www.synaptogen.com/

Market Information (as of February 3, 2021):
Symbol: SNPX
Stock Price: $2.80
Market Cap: $39,291,045
Outstanding Shares: 14,032,516
Warrants, options & preferred stock:

Pre-funded Warrants:
- 333,333 Pre-funded Warrants to purchase 333,333 shares of Common Stock, with an exercise price of $0.01 per share ($3,333)

Investor Warrants (expires February 2022):
- 9,335,533 Series E Warrants to purchase 9,335,533 shares of Common Stock, with an exercise price of $2.1275 per share ($19,861,346)

Spin-off Warrants (expires December 2, 2025):
- 157,792 Series A Warrants to purchase up to 157,792 shares of Common Stock with an exercise price of $49.70 per share ($7,842,262)
- 623,250 Series B Warrants to purchase up to 623,250 shares of Common Stock with an exercise price of $19.88 per share ($12,390,210)
- 908,464 Series C Warrants to purchase up to 908,464 shares of Common Stock with an exercise price of $9.94 per share ($9,030,132)
- 2,221,820 Series D Warrants to purchase up to 2,221,820 shares of Common Stock with an exercise price of $3.98 per share ($8,842,844)

Investor Warrants (expires January 25, 2026):
- 9,335,533 Series F Warrants to purchase up to 9,335,533 shares of Common Stock with an exercise price of $1.725 per share ($16,103,794)
 
Placement Agent Warrants (expires January 29, 2026):
- 933,553 Placement Agent Warrants to purchase up to 933,553 shares of Common Stock with an exercise price of $1.725 per share ($1,610,379)
 
To be raised from exercised warrants: $75,684,300
Fully diluted shares (Outstanding Shares + Warrants): 37,881,794
Fully diluted market cap: $106,069,023

Reports:
Roth report (2018): https://pdfhost.io/v/i@2x9BB+F_37943455120180308NTRPRothInitpdf.pdf
Maxim report (2018): https://pdfhost.io/v/agpp@2Q+o_379427337NTRPinitiationpdf.pdf
Janney report (2019): https://pdfhost.io/v/iQV43NGcT_413879072NTRPInitiation06182019pdf.pdf

Press Releases:
Phase 2a results (2015): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-its-phase-2a-study-of-bryostatin-1-in-alzheimers-disease-300038367.html

Exploratory Phase 2b results (2017): https://www.prnewswire.com/news-releases/neurotrope-announces-positive-top-line-results-from-phase-2-study-of-bryostatin-1-for-moderate-to-severe-alzheimers-disease-300448563.html
Exploratory Phase 2b analysis (2018): https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html

Confirmatory Phase 2b results (2019): https://www.prnewswire.com/news-releases/neurotrope-announces-top-line-results-from-confirmatory-phase-2-study-of-bryostatin-1-in-moderate-to-severe-alzheimers-disease-300913655.html
Confirmatory Phase 2b analysis (2020): https://www.prnewswire.com/news-releases/neurotrope-provides-corporate-update-after-completing-bryostatin-1-data-analysis-for-advanced-alzheimers-disease-trial-300991105.html

Scientific Articles:
[P2a & CU results] "Bryostatin Effects on Cognitive Function and PKC epsilon in Alzheimer’s Disease Phase IIa and Expanded Access Trials" (2017): https://pdfhost.io/v/XAcILs@Hc_jad2F20172F5822Fjad582jad1701612Fjad58jad170161pdf.pdf
[Exploratory P2b results] "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Ef?cacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer’s Disease" (2018): https://pdfhost.io/v/GEa58CPiF_farlow2018pdf.pdf
[Memantine results] "Memantine in Moderate-to-Severe Alzheimer's Disease" (2003): https://www.nejm.org/doi/full/10.1056/NEJMoa013128
More scientific articles: https://pdfhost.io/v/.~Rt1cU63_bryo1.pdf

Patents:
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Patents by Daniel L. Alkon (grants only): http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L.&d=PTXT
Patents by Daniel L. Alkon (applications only): http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=0&p=1&f=S&l=50&Query=IN%2FAlkon-Daniel-L&d=PG01

Media:
"A new era for treating diseases of the brain" (2008): https://youtu.be/W1pdg1kvQHI
"Rockefeller Institute drug provides hope for Alzheimer’s treatment" (2015): https://www.wvgazettemail.com/news/rockefeller-institute-drug-provides-hope-for-alzheimer-s-treatment/article_bf5bab5f-e40e-5f47-95ca-666f14b795e0.html
"The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam" (2018): https://www.genengnews.com/magazine/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/
"Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon" (2018): https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/
"Company Seeks to Prove Marine-Derived Alzheimer's Drug Is No Fish Story" (2019): https://soundcloud.com/levine-media-group/company-seeks-to-prove-marine-derived-alzheimers-drug-is-no-fish-story
"Pizza Hut co-founder’s compassionate-care Alzheimer’s trial leads to hope for others" (2019): https://www.kansas.com/news/business/biz-columns-blogs/carrie-rengers/article229253744.html
"After A Big Failure, Scientists And Patients Hunt For A New Type Of Alzheimer's Drug" (2019): https://www.npr.org/sections/health-shots/2019/05/03/718754791/after-a-big-failure-scientists-and-patients-hunt-for-a-new-type-of-alzheimers-d
Dr. Alkon at Alzheimer's Solutions Conference (2019): https://www.youtube.com/watch?v=bP5GcAplXls
How an Alzheimer’s ‘cabal’ thwarted progress toward a cure (2019): https://www.statnews.com/2019/06/25/alzheimers-cabal-thwarted-progress-toward-cure/
Charles Ryan On Treating Alzheimer's Disease (2019): https://tdameritradenetwork.com/video/rB4AoWt8Hk2Ba5865CUHvQ
The Impacts of Alzheimer's Disease are Growing (2019): https://www.youtube.com/watch?v=x4NkJqASGZc
Ellis Martin Report with Neurotrope's Dr Daniel Alkon: Successfully Reversing Alzheimer's Disease? (2019): https://www.youtube.com/watch?v=KwkiUj2uGgA

Links:
Investor relations: https://www.synaptogen.com/ir/
SEC filings:
Neurotrope Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001513856
Synaptogenix Inc: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001571934
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
BryoLogyx: https://bryologyx.com/
NeuroDiagnostics: https://www.ndx-discern.com/
Ongoing trial: https://clinicaltrials.gov/ct2/show/NCT04538066

 
SNPX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#16438  Sticky Note This has nothing to do with gene editing. Cyosol 10/23/20 01:55:42 PM
#16239  Sticky Note Neurotrope is a front for old money and XenaLives 08/29/20 06:05:05 AM
#16205  Sticky Note FDA trial results. Includes Statistical plan and trial runncoach 07/08/20 08:25:53 PM
#17034   One of the listing requirements is that any Cyosol 03/02/21 01:21:35 AM
#17033   Special stockholder meeting on April 2 about approving Cyosol 03/02/21 01:11:07 AM
#17032   It certainly could play out that way and runncoach 03/01/21 01:38:31 PM
#17031   A couple GUESSES regarding the near-term stock price. Battle Ready 03/01/21 09:31:17 AM
#17030   This is really interesting stuff for those that runncoach 02/28/21 02:37:57 PM
#17029   Maybe you're right. Personally I'm expecting it to Cyosol 02/26/21 07:32:29 PM
#17028   20 million to fund a 9 million dollar runncoach 02/26/21 06:43:52 PM
#17027   I wouldn't be so sure about that pipeline Cyosol 02/26/21 06:19:09 PM
#17026   Hard to say but that is my take. runncoach 02/26/21 06:10:33 PM
#17025   The company stated. “ The availability of increased Theburg 02/26/21 06:04:32 PM
#17024   Maybe they will and maybe they won't. runncoach 02/26/21 02:13:25 PM
#17023   Anavex will probably be in trial for Fragile XenaLives 02/26/21 01:59:48 PM
#17022   FragileX abstract. Very interesting stuff. I runncoach 02/25/21 10:39:35 PM
#17021   I'm just not familiar with that area red. runncoach 02/25/21 12:29:58 PM
#17020   Link currently available for today's virtual poster. runncoach 02/25/21 12:07:19 PM
#17019   What about spinal injuries? redspinelpinktopaz 02/25/21 11:01:06 AM
#17018   PR on some upcoming conference presentations out this runncoach 02/25/21 09:10:48 AM
#17017   It sounded like MS and Fragile X are runncoach 02/24/21 03:10:03 PM
#17016   Thanks for the update from this conference, Coach. InTheTrenches 02/24/21 03:01:18 PM
#17015   No doubt the 42 week secondary endpoint it runncoach 02/23/21 01:13:34 PM
#17014   28 weeks being the primary endpoint makes this Cyosol 02/23/21 12:57:49 PM
#17013   It's possible I suppose but its the 28 runncoach 02/22/21 08:07:24 PM
#17012   I don't think the FDA needs more safety Cyosol 02/22/21 07:42:51 PM
#17011   I forgot to mention that if they don't Cyosol 02/22/21 07:36:46 PM
#17010   Great overview, especially your rationale. Thank you DRK123 02/22/21 01:10:50 PM
#17009   It certainly is big in the sense that runncoach 02/22/21 11:56:56 AM
#17008   big positive on SAVA this morning redspinelpinktopaz 02/22/21 09:26:29 AM
#17007   We might not know the cause yet, but Cyosol 02/17/21 06:33:32 PM
#17006   I followed a company one time where it runncoach 02/17/21 04:57:55 PM
#17005   I must've misunderstood it then. Cyosol 02/17/21 04:44:11 PM
#17004   I thought they applied for 510k approval even runncoach 02/17/21 02:45:54 PM
#17003   Thanks for the summary. If the closing price Cyosol 02/17/21 02:31:43 PM
#17002   We are where we should have been a runncoach 02/17/21 01:00:17 PM
#17001   Great recap—thank you. It appears this is all DRK123 02/17/21 12:53:50 PM
#17000   Good presentation. Not sure how many were runncoach 02/17/21 12:07:33 PM
#16999   RE:Conference today. Anyone know how this works? runncoach 02/17/21 10:51:14 AM
#16998   Wow... I didn’t realize Dr. Tuchman was the DRK123 02/17/21 10:40:43 AM
#16997   Thanks. Good stuff. I'm signed up runncoach 02/17/21 10:33:32 AM
#16996   Looks great, thanks Cyosol! Battle Ready 02/17/21 09:29:02 AM
#16995   New presentation: Cyosol 02/17/21 09:02:24 AM
#16994   Just updated the ibox with more recent market information. Cyosol 02/14/21 07:32:09 AM
#16993   That would be huge, any one of those DRK123 02/13/21 03:05:16 PM
#16992   If we start a fragile X trial it runncoach 02/13/21 01:56:05 PM
#16991   Agree. And would be fantastic to see an DRK123 02/13/21 01:45:02 PM
#16990   I'll say again, I don't believe they spent runncoach 02/13/21 01:36:24 PM
#16989   I concur. DRK123 02/13/21 01:10:34 PM
#16986   Fooled the NIH. Must be a good one! runncoach 02/12/21 03:15:38 PM
#16985   SYNTAPTOGENIX THE PENNY STOCK SCAM FORMERLY KNOWN AS rayovacAAA 02/12/21 03:10:32 PM
#16984   At least the company is back out and runncoach 02/12/21 12:39:23 PM
#16983   Yeah I'm a pretty patient person. runncoach 02/11/21 02:09:13 PM
PostSubject
Consent Preferences